Oltmans Curtis Gale 4
4 · Fulcrum Therapeutics, Inc. · Filed Apr 28, 2023
Insider Transaction Report
Form 4
Oltmans Curtis Gale
Chief Legal Officer
Transactions
- Award
Stock Option (right to buy)
2023-04-26+127,500→ 127,500 totalExercise: $2.58Exp: 2033-04-25→ Common Stock (127,500 underlying)
Footnotes (1)
- [F1]These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date.